Altogen Labs A498 Xenograft Service Kidney Cancer
Altogen Labs http://altogenlabs.com provides xenograft services http://altogenlabs.com/xenograft-mode.... The exact cause of renal cancer is unknown; therefore, scientists often rely on preclinical research in the development of novel treatment regimens and innovative kidney therapeutics. Human tumor xenografting allows greater understanding of the biology of the disease and could aid in finding new treatment solutions. The A498 cell line is a suitable host for studying various types of kidney cancer.
The A498 human kidney cell line is used to create the CDX (Cell Line Derived Xenograft) A498 xenograft mouse model that is frequently used in preclinical research involving apoptosis thru activation of JNK pathway and for in vivo studies of therapeutic compounds targeting kidney cancer cells. The A498 xenograft model is useful for biomedical research related to kidney cancer.
Xenografting is the transplantation of tissue from one species into another.
Xenografting has been established as benchmark studies in pre-clinical cancer research.
Typically, immunodeficient mice serve as hosts for a wide variety of human tumors, effectively serving as models for human subjects.
Xenografting is a complete and accurate study of tumor growth and the activity of drug administration.
-A498 Xenograft Model
Sample Cell Lines Available
-A498 Xenograft Model
Advantages of Xenografting
Develop new therapeutic agents quickly, efficiently and cost-effectively
Evaluate the efficacy and toxicity of potential therapeutic agents
Evaluate target compound activity using in vivo system (human cells)
Predict cytotoxicity of cancer drugs
-A498 Xenograft Model
Basic Xenograft Study
Xenograft studies can be designed to:
Identify lead compounds
Optimize dose schedules
Identify combination strategies
-A498 Xenograft Model
Routes of drug administration:
Intratumoral
Intramuscular
Oral gavage
Intravenous
Intratracheal
Subcutaneous
Intraperitoneal
Continuous infusion
Intranasal
Using cutting-edge micro-injection techniques
-A498 Xenograft Model
Following options are available for the A498 xenograft model:
A498 Tumor Growth Delay (TGD; latency)
A498 Tumor Growth Inhibition (TGI)
Dosing frequency and duration of dose administration
A498 tumor immunohistochemistry
Alternative cell engraftment sites (orthotopic transplantation, tail vein injection and left ventricular injection for metastasis studies, injection into the mammary fat pad, intraperitoneal injection)
Blood chemistry analysis
Toxicity and survival (optional: performing a broad health observation program)
Gross necropsies and histopathology
Positive control group employing cyclophosphamide, at a dosage of 50 mg/kg administered by intramuscular injection to the control group daily for the study duration
Lipid distribution and metabolic assays
Imaging studies: Fluorescence-based whole body imaging, MRI
-A498 Xenograft Model
Altogen Labs’ team of scientists carries extensive experience in Xenograft model research.
Altogen Labs is compliant as a Good Laboratory Practices (GLP) environment, which is required by the FDA for pre-clinical research.
Our Altogen Labs’ Xenograft services are extensive, rigorous, and flexible.
Contact us to discuss Xenograft model details, timeline estimates, and price quotes!
Connect to Altogen Labs:
LinkedIn - / altogen-labs
Twitter - https://twitter.com/altogen?lang=en
Facebook - / altogen.cro